EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation

Holger Babbe iD, Thomas B Sundberg, Mark Tichenor iD, Mark Seierstad, Genesis Bacani, James Berstler iD, Wenying Chai, Leon Chang, De Michael Chung iD, Kevin Coe, Bernard Collins, Michael Finley iD und 32 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2307086120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Holger Babbe und 43 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research and Development, LLC., Spring House, PA 19477. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cyclic AMP Response Element-Binding Protein. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The salt-inducible kinases (SIK) 1–3 are key regulators of pro- versus anti-inflammatory cytokine responses during innate immune activation. The lack of highly SIK-family or SIK isoform-selective inhibitors suitable for repeat, oral dosing has limited the study of the optimal SIK isoform selectivity profile for suppressing inflammation in vivo. To overcome this challenge, we devised a structure-based design strategy for developing potent SIK inhibitors that are highly selective against other kinases by engaging two differentiating features of the SIK catalytic site. This effort resulted in SIK1/2-selective probes that inhibit key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3) as detected with an internally generated phospho-Ser329-CRTC3-specific antibody. These inhibitors also suppress production of pro-inflammatory cytokines while inducing anti-inflammatory interleukin-10 in activated human and murine myeloid cells and in mice following a lipopolysaccharide challenge. Oral dosing of these compounds ameliorates disease in a murine colitis model. These findings define an approach to generate highly selective SIK1/2 inhibitors and establish that targeting these isoforms may be a useful strategy to suppress pathological inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCyclic AMP Response Element-Binding ProteinMiceHumansAnimalsCytokinesInflammationProtein IsoformsAnti-Inflammatory AgentsImmunity, InnateTranscription Factors

Stichwörter der Autor:innen

immunological disordersinflammatory bowel diseasekinase inhibitorsmedicinal chemistrystructure-based drug design

Substanzen

Protein Serine-Threonine KinasesCyclic AMP Response Element-Binding ProteinCytokinesProtein IsoformsAnti-Inflammatory AgentsSIK1 protein, humanCRTC3 protein, mouseTranscription Factors

Autor:innen und Institutionen

  • Janssen Research and Development, LLC., Spring House, PA 19477.
  • Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142.
  • Janssen Research and Development, LLC., San Diego, CA 92121.
  • Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114.
  • Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.
  • Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142.

ORCID-Profile: Holger Babbe, Mark Tichenor, James Berstler, De Michael Chung, Michael Finley, Christopher T Lemke, Marie-Laure Rives, Ruth Steele, Javier Suarez, Nathan Majewski, Luvena L Ong, Gavin Hirst, Nilufer Seth, Daniel B Graham

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Babbe, H., Sundberg, T. B., Tichenor, M., Seierstad, M., Bacani, G., Berstler, J., Chai, W., Chang, L., Chung, M., Coe, K., Collins, B., Finley, M., Guletsky, A., Lemke, C. T., Mak, P. A., Mathur, A., Mercado-Marin, E. V., Metkar, S., Raymond, D. D., …, & Towne, J. E. (2024). Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2307086120

Vancouver

Babbe H, Sundberg TB, Tichenor M, Seierstad M, Bacani G, Berstler J, et al. Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2307086120

BibTeX
@article{Babbe2024,
  author = {Babbe, Holger and Sundberg, Thomas B and Tichenor, Mark and Seierstad, Mark and Bacani, Genesis and Berstler, James and Chai, Wenying and Chang, Leon and Chung, De Michael and Coe, Kevin and Collins, Bernard and Finley, Michael and Guletsky, Alexander and Lemke, Christopher T and Mak, Puiying A and Mathur, Ashok and Mercado-Marin, Eduardo V and Metkar, Shailesh and Raymond, Donald D and Rives, Marie-Laure and Rizzolio, Michele and Shaffer, Paul L and Smith, Russell and Smith, Jacqueline and Steele, Ruth and Steffens, Helena and Suarez, Javier and Tian, Gaochao and Majewski, Nathan and Volak, Laurie P and Wei, Jianmei and Desai, Prerak T and Ong, Luvena L and Koudriakova, Tatiana and Goldberg, Steven D and Hirst, Gavin and Kaushik, Virendar K and Ort, Tatiana and Seth, Nilufer and Graham, Daniel B and Plevy, Scott and Venable, Jennifer D and Xavier, Ramnik J and Towne, Jennifer E},
  title = {Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2307086120}
}
Kostenlos starten →